

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * STN Columbus * * * * *
```

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10506579\10506579_elected specie.str
```



```

chain nodes :
2  3  4  5  6  7  8  9 10 11 18 19 20 21 22 23 24 25 26 27 28 29 30
31 32 38 39 40
ring nodes :
1 12 13 14 15 16 17 33 34 35 36 37
chain bonds :
1-2 2-3 3-4 4-5 5-6 5-18 6-7 6-20 7-8 8-9 8-21 9-10 9-32 10-11 11-12
18-19 21-22 22-23 23-24 24-25 24-26 26-27 26-28 27-31 28-29 28-30 35-38
38-39 38-40
ring bonds :
1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37
exact/norm bonds :
3-4 4-5 6-7 6-20 7-8 9-10 9-32 10-11 18-19 23-24 24-25 24-26 26-27
26-28 38-39 38-40
exact bonds :
1-2 2-3 5-6 5-18 8-9 8-21 11-12 21-22 22-23 27-31 28-29 28-30 35-38
normalized bonds :
1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37

```

```

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom
35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 40:CLASS

```

```

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

```

```

SINCE FILE      TOTAL
ENTRY          SESSION
8.28           8.49

```

```

FILE 'REGISTRY' ENTERED AT 08:14:42 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

```

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10506579\10506579 elected specie.str



chain nodes :
2 3 4 5 6 7 8 9 10 11 18 19 20 21 22 23 24 25 26 27 28 29 30
31 32 38 39 40
ring nodes :
1 12 13 14 15 16 17 33 34 35 36 37
chain bonds :
1-2 2-3 3-4 4-5 5-6 5-18 6-7 6-20 7-8 8-9 8-21 9-10 9-32 10-11 11-12
18-19 21-22 22-23 23-24 24-25 24-26 26-27 26-28 27-31 28-29 28-30 35-38
38-39 38-40
ring bonds :
1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37
exact/norm bonds :
3-4 4-5 6-7 6-20 7-8 9-10 9-32 10-11 18-19 23-24 24-25 24-26 26-27
26-28 38-39 38-40
exact bonds :
1-2 2-3 5-6 5-18 8-9 8-21 11-12 21-22 22-23 27-31 28-29 28-30 35-38
normalized bonds :
1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom
35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 40:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 08:15:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1 exact full

FULL SEARCH INITIATED 08:15:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA EXA FUL L1

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

69.97

78.46

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:27:52 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 08:52:40 ON 14 JUL 2008
 FILE 'REGISTRY' ENTERED AT 08:52:40 ON 14 JUL 2008
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION


FULL ESTIMATED COST

69.97

78.46

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
 files\10506579\10506579 elected specie.str



chain nodes :

2 3 4 5 6 7 8 9 10 11 18 19 20 21 22 23 24 25 26 27 28 29 30
 31 32 38 39 40

ring nodes :

1 12 13 14 15 16 17 33 34 35 36 37

chain bonds :

1-2 2-3 3-4 4-5 5-6 5-18 6-7 6-20 7-8 8-9 8-21 9-10 9-32 10-11 11-12
 18-19 21-22 22-23 23-24 24-25 24-26 26-27 26-28 27-31 28-29 28-30 35-38
 38-39 38-40

ring bonds :

1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37

exact/norm bonds :

3-4 4-5 6-7 6-20 7-8 9-10 9-32 10-11 18-19 23-24 24-25 24-26 26-27
 26-28 38-39 38-40

exact bonds :

1-2 2-3 5-6 5-18 8-9 8-21 11-12 21-22 22-23 27-31 28-29 28-30 35-38

normalized bonds :

1-13 1-17 12-33 12-37 13-14 14-15 15-16 16-17 33-34 34-35 35-36 36-37

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom
 35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 40:CLASS

L4

STRUCTURE UPLOADED

=> d 14
L4 HAS NO ANSWERS
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search 14 sss sam
SAMPLE SEARCH INITIATED 08:53:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> search 14 sss full
FULL SEARCH INITIATED 08:53:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L4

=> logoff hold
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 248.79 257.28

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:53:40 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x



LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 08:58:10 ON 14 JUL 2008
FILE 'REGISTRY' ENTERED AT 08:58:10 ON 14 JUL 2008
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 248.79 257.28

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10506579\10506579 1st generic stab .str



```

chain nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  19  20  21
chain bonds :
1-2  2-3  3-4  3-10  4-5  5-6  5-11  6-7  6-13  7-8  8-9  9-14  11-12  14-15  20-21

exact/norm bonds :
1-2  3-4  3-10  4-5  6-7  6-13  7-8  8-9  9-14  11-12  14-15
exact bonds :
2-3  5-6  5-11  20-21

```

G1:O,S,N

G2:N, [*1], [*2]

G3:C,O,S,N

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 19:CLASS 20:CLASS
21:CLASS

```


L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search 17 sss sam

SAMPLE SEARCH INITIATED 08:59:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 68070 TO ITERATE

2.9% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1345856 TO 1376944

PROJECTED ANSWERS: 2022 TO 3422

L8 4 SEA SSS SAM L7

=> d scan

L8 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Prolinamide, N-acetyl-L-tryptophyl-L-phenylalanyl-L-leucyl-L- α -
aspartyl-L-asparaginyl-L-alanyl- (9CI)


SQL 7


MF C44 H58 N10 O11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L8 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN α 7-19-Corticotropin, 8-D-lysine-9-L-phenylalanine-19-L-prolinamide-
 (9CI)
 SQL 13
 MF C73 H122 N24 O13
 CI COM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




```

L8      4 ANSWERS      REGISTRY  COPYRIGHT 2008 ACS on STN
IN      Gastrin-releasing peptide (swine), 16-L-prolinamide-17-de-L-arginine-18-
        deglycine-19-de-L-asparagine-20-de-L-histidine-21-de-L-tryptophan-22-de-L-
        alanine-23-de-L-valine-24-deglycine-25-de-L-histidine-26-de-L-leucine-27-
        de-L-methioninamide- (9CI)
SQL     16
MF      C70 H116 N18 O19 S


```

Absolute stereochemistry.

PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L8 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Prolinamide, L-leucyl-L-prolyl-L- α -glutamyl-L-tyrosyl-L-
tyrosylglycyl-L- α -glutamyl-L-asparaginyl-L-leucyl-L- α -aspartyl-
L-alanyl-L-leucyl-L-tryptophyl-L- α -aspartyl-L-alanyl-L-leucyl-L-
threonylglycyl-L-tryptophyl-L-valyl-L- α -glutamyl-L-tyrosyl- (9CI)

SQL 23


MF C129 H177 N27 O38

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

252.01

260.50

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:02:31 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 09:18:02 ON 14 JUL 2008

FILE 'REGISTRY' ENTERED AT 09:18:02 ON 14 JUL 2008

COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

252.01

260.50

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10506579\10506579 modified 1st generic stab .str



```

chain nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  16  17  18
chain bonds :
1-2  2-3  3-4  3-10  4-5  5-6  5-11  6-7  6-12  7-8  8-9  9-13  13-14  17-18
exact/norm bonds :
1-2  2-3  3-4  3-10  4-5  6-7  6-12  7-8  8-9  9-13  13-14
exact bonds :
5-6  5-11  17-18

```

G1:O,S,N

G2:N, [*1], [*2]

G3:C,O,S,N

G4:CH,N

```

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:Atom
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS

```

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search 19 sss sam

SAMPLE SEARCH INITIATED 09:18:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 68326 TO ITERATE

2.9% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1350948 TO 1382092

PROJECTED ANSWERS: 2032 TO 3434

L10 4 SEA SSS SAM L9

=> d scan

L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN


IN L-Prolinamide, L-leucyl-L-prolyl-L- α -glutamyl-L-tyrosyl-L-tyrosylglycyl-L- α -glutamyl-L-asparaginyl-L-leucyl-L- α -aspartyl-L-alanyl-L-leucyl-L-tryptophyl-L- α -aspartyl-L-alanyl-L-leucyl-L-threonylglycyl-L-tryptophyl-L-valyl-L- α -glutamyl-L-tyrosyl- (9CI)

SQL 23


MF C129 H177 N27 O38

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Dermorphin, 4-D-alanine-6-D-prolinamide-7-de-L-serinamide- (9CI)
 SQL 6
 MF C38 H47 N7 O8

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3-31- α -Epidermal growth factor (mouse salivary gland reduced),
 3-(N-acetyl-L-tyrosine)-31-L-cysteinamide-, cyclic
 (6 \rightarrow 14), (20 \rightarrow 31)-bis(disulfide) (9CI)
 SQL 29
 MF C135 H191 N33 O46 S5

RELATED SEQUENCES AVAILABLE WITH SEQLINK



Absolute stereochemistry.






* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *






IN L-Prolinamide, glycyl-L-lysyl-L-alanyl-L-lysyl-L-valyl-L-isoleucyl-L-
 cysteinyl-L-leucyl-L-threonyl-L-valyl-L-leucyl-L-alanyl-L-seryl-L-valyl-L-
 arginyl-L-isoleucyl-L-tyrosyl-L-tyrosyl-L-glutaminyl-L-tyrosyl-L-arginyl-L-
 arginyl-L-valyl-L-lysyl- (9CI)
 SQL 25
 MF C135 H227 N39 O31 S


PAGE 1-A



PAGE 1-B







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search 19 sss full
 FULL SEARCH INITIATED 09:19:07 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1362278 TO ITERATE

53.8% PROCESSED	733451 ITERATIONS	2399 ANSWERS
70.0% PROCESSED	953387 ITERATIONS	2809 ANSWERS
72.8% PROCESSED	991764 ITERATIONS	2857 ANSWERS
73.4% PROCESSED	1000000 ITERATIONS	2858 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.51

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1362278 TO 1362278
 PROJECTED ANSWERS: 3706 TO 4080

L11 2858 SEA SSS FUL L9

=> save temp l11 rawmstrset/a
 ANSWER SET L11 HAS BEEN SAVED AS 'RAWMSTRSET/A'

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	431.75	440.24

FILE 'CAPLUS' ENTERED AT 09:20:25 ON 14 JUL 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> l11

L12 653 L11

=> urokinase

12760 UROKINASE

54 UROKINASES

L13 12764 UROKINASE

(UROKINASE OR UROKINASES)

=> l12 and l13

L14 26 L12 AND L13

=> arg

37662 ARG

114 ARGS

L15 37753 ARG

(ARG OR ARGS)

=> l15 and l15

L16 37753 L15 AND L15

=> l14 and l15

L17 0 L14 AND L15

=> arginine

122885 ARGININE

1200 ARGININES

L18 123282 ARGININE

(ARGININE OR ARGININES)

=> l14 and l18

L19 4 L14 AND L18

=> d l19 1-4 ti fbib abs

L19 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of proteinase inhibitors in the treatment of autoimmune diseases

AN 2003:678650 CAPLUS

DN 139:207776

TI Use of proteinase inhibitors in the treatment of autoimmune diseases

IN Jacob, Uwe; Sondermann, Peter; Huber, Robert

PA Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., Germany
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070229	A2	20030828	WO 2003-EP1807	20030221
	WO 2003070229	A3	20040304		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				DE 2002-10207744	A 20020222
				DE 2002-10241411	A 20020906
	DE 10241411	A1	20030904	DE 2002-10241411	20020906
				DE 2002-10207744	A1 20020222
	AU 2003206945	A1	20030909	AU 2003-206945	20030221
				DE 2002-10207744	A 20020222
				DE 2002-10241411	A 20020906
				WO 2003-EP1807	W 20030221

OS MARPAT 139:207776

AB The invention discloses the use of at least one substance that inhibits proteases, especially serine proteases, in the treatment of diseases or conditions that are characterized by excess immunoreactivity, especially excessive or undesired activation of immune cells, production of antibodies, or complement activation.

L19 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

TI Identification of target-specific folding sites in peptides and proteins

AN 2002:637788 CAPLUS

DN 137:179841

TI Identification of target-specific folding sites in peptides and proteins

IN Sharma, Shubh D.; Shi, Yi-Qun

PA Palatin Technologies, Inc., USA

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064734	A2	20020822	WO 2001-US50075	20011219
	WO 2002064734	A3	20031120		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2000-256842P	P 20001219

			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
CA 2436789	A1	20020822	CA 2001-2436789		20011219
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	W	20011219
AU 2002246807	A1	20020828	AU 2002-246807		20011219
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	W	20011219
EP 1379283	A2	20040114	EP 2001-994412		20011219
EP 1379283	B1	20080213			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	W	20011219
JP 2005501220	T	20050113	JP 2002-565049		20011219
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	W	20011219
AT 385811	T	20080315	AT 2001-994412		20011219
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
US 20040248212	A1	20041209	US 2004-769695		20040130
US 7351690	B2	20080401			
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	A1	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617
US 20050282739	A1	20051222	US 2005-188552		20050725
US 7385025	B2	20080610			
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	A2	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617
			US 2004-769695	A2	20040130
			US 2004-590933P	P	20040723

PATENT FAMILY INFORMATION:

FAN 2004:740117

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004075830	A2	20040910	WO 2004-US2933	20040202
	WO 2004075830	A3	20060928		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				

GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2003-444129P P 20030131
				US 2004-769695 A 20040130
US 20040248212	A1	20041209		US 2004-769695 20040130
US 7351690	B2	20080401		
				US 2000-256842P P 20001219
				US 2001-304835P P 20010711
				US 2001-327835P P 20011004
				WO 2001-US50075 A1 20011219
				US 2003-444129P P 20030131
				US 2003-464117 A2 20030617
CA 2516750	A1	20040910		CA 2004-2516750 20040202
				US 2003-444129P P 20030131
				US 2004-769695 A 20040130
				WO 2004-US2933 W 20040202
EP 1594442	A2	20051116		EP 2004-737267 20040202
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
				US 2003-444129P P 20030131
				US 2004-769695 A 20040130
				WO 2004-US2933 W 20040202
JP 2007525641	T	20070906		JP 2006-503255 20040202
				US 2003-444129P P 20030131
				US 2004-769695 A 20040130
				WO 2004-US2933 W 20040202
FAN	2004:1060669			
	PATENT NO.			
	KIND	DATE	APPLICATION NO. DATE	
	-----	-----	-----	
PI	US 20040248212	A1	20041209	US 2004-769695 20040130
	US 7351690	B2	20080401	
				US 2000-256842P P 20001219
				US 2001-304835P P 20010711
				US 2001-327835P P 20011004
				WO 2001-US50075 A1 20011219
				US 2003-444129P P 20030131
				US 2003-464117 A2 20030617
WO 2002064734	A2	20020822		WO 2001-US50075 20011219
WO 2002064734	A3	20031120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2000-256842P P 20001219
				US 2001-304835P P 20010711
				US 2001-327835P P 20011004
US 20050014193	A1	20050120		US 2003-464117 20030617
CA 2516750	A1	20040910		CA 2004-2516750 20040202
				US 2003-444129P P 20030131
				US 2004-769695 A 20040130
				WO 2004-US2933 W 20040202
WO 2004075830	A2	20040910		WO 2004-US2933 20040202
WO 2004075830	A3	20060928		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,			

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1594442 A2 20051116 EP 2004-737267 20040202
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2007525641 T 20070906 JP 2006-503255 20040202
 US 20050282739 A1 20051222 US 2003-444129P P 20030131
 US 7385025 B2 20080610 US 2004-769695 A 20040130
 WO 2004-US2933 W 20040202
 US 2005-188552 20050725

US 2000-256842P P 20001219
 US 2001-304835P P 20010711
 US 2001-327835P P 20011004
 WO 2001-US50075 A2 20011219
 US 2003-444129P P 20030131
 US 2003-464117 A2 20030617
 US 2004-769695 A2 20040130
 US 2004-590933P P 20040723

FAN 2005:59906

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI

US 20050014193
 US 20040248212
 US 7351690

A1
 A1
 B2

20050120
 20041209
 20080401

US 2003-464117 20030617
 US 2004-769695 20040130

US 2000-256842P P 20001219
 US 2001-304835P P 20010711
 US 2001-327835P P 20011004
 WO 2001-US50075 A1 20011219
 US 2003-444129P P 20030131
 US 2003-464117 A2 20030617
 US 2005-188552 20050725

US 20050282739
 US 7385025

A1
 B2

20051222
 20080610

US 2000-256842P P 20001219
 US 2001-304835P P 20010711
 US 2001-327835P P 20011004
 WO 2001-US50075 A2 20011219
 US 2003-444129P P 20030131
 US 2003-464117 A2 20030617
 US 2004-769695 A2 20040130
 US 2004-590933P P 20040723

FAN 2005:1333961

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI

US 20050282739
 US 7385025

A1
 B2

20051222
 20080610

US 2005-188552 20050725

US 2000-256842P P 20001219
 US 2001-304835P P 20010711
 US 2001-327835P P 20011004
 WO 2001-US50075 A2 20011219
 US 2003-444129P P 20030131
 US 2003-464117 A2 20030617
 US 2004-769695 A2 20040130

			US 2004-590933P	P	20040723
WO 2002064734	A2	20020822	WO 2001-US50075		20011219
WO 2002064734	A3	20031120			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
US 20050014193	A1	20050120	US 2003-464117		20030617
US 20040248212	A1	20041209	US 2004-769695		20040130
US 7351690	B2	20080401			
			US 2000-256842P	P	20001219
			US 2001-304835P	P	20010711
			US 2001-327835P	P	20011004
			WO 2001-US50075	A1	20011219
			US 2003-444129P	P	20030131
			US 2003-464117	A2	20030617

AB The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a min. of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The invention further provides methods to determine the specific sequence and local three-dimensional structure of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biol. activity of interest and methods to determine the pharmacophore of receptors or targets of interest. The invention provides for defined pharmacophores or receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.

L19 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of peptides as inhibitors of urokinase and blood vessel formation
 AN 2002:609967 CAPLUS
 DN 137:140782
 TI Preparation of peptides as inhibitors of urokinase and blood vessel formation
 IN Brunck, Terence K.; Tamura, Susan Y.
 PA Corvas International, Inc., USA
 SO U.S., 68 pp., Cont. of U.S. Ser. No. 121,921.
 CODEN: USXXAM
 DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6432922	B1	20020813	US 1999-359929	19990722
				US 1998-121921	A2 19980724
	US 6576613	B1	20030610	US 1998-121921	19980724

PATENT FAMILY INFORMATION:

FAN 2000:84824

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005245	A2	20000203	WO 1999-US16577	19990722
	WO 2000005245	A3	20000420		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1998-121921	A 19980724
	US 6576613	B1	20030610	US 1998-121921	19980724
	CA 2338524	A1	20000203	CA 1999-2338524	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	AU 9950058	A	20000214	AU 1999-50058	19990722
	AU 772024	B2	20040408		
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	EP 1100814	A2	20010523	EP 1999-934173	19990722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	JP 2002521386	T	20020716	JP 2000-561201	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	NZ 509400	A	20031219	NZ 1999-509400	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722

OS MARPAT 137:140782

AB Peptides R1-X-NHCH(R2)CON(R3)CH(R4)CONHR5 [X = SO2, NR'SO2, CO, O2C, NHCO, P(O)R', or a direct link, where R' = H, alkyl, aryl, aralkyl; R1 = (cyclo)alkyl, heterocycloalkyl, aryl, etc.; R2 = H, CH2CH2OA2, CHR6OH, CHR6OA2, CH2NH-X'-R6, where A2 = CO2R9 or COR9; X' = CO or CO2; R6 = H, Me, phenethyl, or benzyl; R9 = (cyclo)alkyl, heterocycloalkyl, aryl, etc.; R3 = H, Me; R4 = H, CH2SMe, CH2OH, CH2CN, alkyl, propargyl, 2-propenyl, vinyl; or R3 and R4 together form prolyl, pipecolyl, azetidine-2-carbonyl, 3- or 4-hydroxyprolyl, 3,4-dehydroprolyl (the carbonyl bearing R4 is in the S configuration); R5 = (S)-CH(CH2R7)CHO or (S)-CH[CH2CH2CH2NHC(:NH)NH2]COCO-A1, where R7 = guanidinoalkyl, 3- or 4-amidinophenyl, 1-amidinopiperidin-3(or 4)-yl and A1 is alkyl- or arylamino (with provisos)] or their pharmaceutically-acceptable salts were prepared as inhibitors of urokinase and blood vessel formation. These compds. have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. Thus, N-(isobutoxycarbonyl)-D-seryl-L-alanylarginal (1) was prepared by the solid-phase method and showed IC50 < 100 nm for inhibition of urokinase-type plasminogen activator (uPA). Compound 1 was also evaluated for inhibition of angiogenesis in vivo and growth of human tumor cells in a chick embryo model.



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of peptides as inhibitors of urokinase and blood
vessel formation
AN 2000:84824 CAPLUS
DN 132:137731
TI Preparation of peptides as inhibitors of urokinase and blood
vessel formation
IN Brunck, Terence K.; Tamura, Susan Y.
PA Corvas International, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2000005245	A2	20000203	WO 1999-US16577	19990722
	WO 2000005245	A3	20000420		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6576613	B1	20030610	US 1998-121921	A 19980724
	CA 2338524	A1	20000203	US 1998-121921	19980724
				CA 1999-2338524	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	AU 9950058	A	20000214	AU 1999-50058	19990722
	AU 772024	B2	20040408		
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	EP 1100814	A2	20010523	EP 1999-934173	19990722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	JP 2002521386	T	20020716	JP 2000-561201	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722
	NZ 509400	A	20031219	NZ 1999-509400	19990722
				US 1998-121921	A 19980724
				WO 1999-US16577	W 19990722

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 6432922	B1	20020813	US 1999-359929	19990722
				US 1998-121921	A2 19980724
	US 6576613	B1	20030610	US 1998-121921	19980724
OS	MARPAT 132:137731				
GI					



AB Title compds. RXNHCH(R1)CON(R2)CH(R4)CONHR3 [X = SO₂, CO, OCO, NHCO; R = alkyl, cycloalkyl, heterocycloalkyl; R1 = HOCH₂, CH₃SCH₂, side-chain or ring of amino acid ; R2 = CH₃, CH₃CH₂, side-chain or ring of amino acid; R3 = CH₃, propargyl; R4 = H; R3R4 = prolyl, 4-hydroxyprolyl, 3-hydroxyprolyl, 3,4-dehydroprolyl;] and stereoisomers are prepared having activities as inhibitors of urokinase and in reducing or inhibiting blood vessel formations. These compds. have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compds. are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathol. conditions wherein blood vessel formation is related to a pathol. condition. The title compds. I and II was prepared

=> d his

(FILE 'HOME' ENTERED AT 08:03:28 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 08:04:09 ON 14 JUL 2008

FILE 'REGISTRY' ENTERED AT 08:14:42 ON 14 JUL 2008

L1	STRUCTURE UPLOADED
L2	0 SEARCH L1 SSS SAM
L3	0 SEARCH L1 EXACT FULL
L4	STRUCTURE UPLOADED
L5	0 SEARCH L4 SSS SAM
L6	0 SEARCH L4 SSS FULL
L7	STRUCTURE UPLOADED
L8	4 SEARCH L7 SSS SAM
L9	STRUCTURE UPLOADED
L10	4 SEARCH L9 SSS SAM
L11	2858 SEARCH L9 SSS FULL
	SAVE TEMP L11 RAWMSTRSET/A

FILE 'CAPLUS' ENTERED AT 09:20:25 ON 14 JUL 2008

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE -3.20 -3.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:08:38 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:52:47 ON 14 JUL 2008
FILE 'CAPLUS' ENTERED AT 10:52:47 ON 14 JUL 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	45.87	486.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	45.87	486.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:52:57 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:07:24 ON 14 JUL 2008
FILE 'CAPLUS' ENTERED AT 12:07:24 ON 14 JUL 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	45.87	486.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

=> logoff hold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
45.87	486.11

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.20	-3.20

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:07:33 ON 14 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:57:36 ON 14 JUL 2008
FILE 'CAPLUS' ENTERED AT 12:57:36 ON 14 JUL 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
45.87	486.11

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.20	-3.20

CA SUBSCRIBER PRICE

=> d his

(FILE 'HOME' ENTERED AT 08:03:28 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 08:04:09 ON 14 JUL 2008

FILE 'REGISTRY' ENTERED AT 08:14:42 ON 14 JUL 2008

L1 STRUCTURE UPLOADED
L2 0 SEARCH L1 SSS SAM
L3 0 SEARCH L1 EXACT FULL
L4 STRUCTURE UPLOADED
L5 0 SEARCH L4 SSS SAM
L6 0 SEARCH L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 4 SEARCH L7 SSS SAM
L9 STRUCTURE UPLOADED
L10 4 SEARCH L9 SSS SAM
L11 2858 SEARCH L9 SSS FULL
SAVE TEMP L11 RAWMSTRSET/A

FILE 'CAPLUS' ENTERED AT 09:20:25 ON 14 JUL 2008

L12 653 L11
L13 12764 UROKINASE
L14 26 L12 AND L13
L15 37753 ARG
L16 37753 L15 AND L15

L17 0 L14 AND L15
L18 123282 ARGININE
L19 4 L14 AND L18
 SAVE TEMP L14 FNDREFS/A
 SAVE TEMP ALL URKINSRCH/L

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	46.35	486.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'REGISTRY' ENTERED AT 12:58:22 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10506579\10506579 2nd generic stab .str



```

chain nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  16  17  18  28  29  30
chain bonds :
1-2  2-3  3-4  3-10  4-5  5-6  5-11  6-7  6-12  7-8  8-9  9-13  11-28  13-14  17-18
    28-29  29-30
exact/norm bonds :
1-2  2-3  3-4  3-10  4-5  6-7  6-12  7-8  8-9  9-13  13-14  29-30
exact bonds :
5-6  5-11  11-28  17-18  28-29

```

G1:O,S,N

G2:N, [*1], [*2]

G3:C,O,S,N

G4:CH,N

```

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:Atom
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS
28:CLASS 29:CLASS 30:CLASS

```

L20 STRUCTURE UPLOADED

=> d 120

L20 HAS NO ANSWERS

L20 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search 120 subset=l11 sss sam

SAMPLE SUBSET SEARCH INITIATED 12:59:31 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

817 TO 1783

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

146 TO 694

L21 21 SEA SUB=L11 SSS SAM L20


=> d scan

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Glutamamide, 3-[1,1'-biphenyl]-4-yl-N-[[(3-carboxyphenyl)methyl]sulfonyl
]-D-alanyl-N1-[[4-(aminoiminomethyl)phenyl]methyl]- (9CI)

MF C36 H38 N6 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):21

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Glutamamide, 5-hydroxy-N-(propylsulfonyl)-D-tryptophyl-N1-[[4-(
 aminoiminomethyl)phenyl]methyl]- (9CI)

MF C27 H35 N7 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Prolinamide, N-acetyl-L-tyrosyl-3-cyclohexyl-L-alanyl-L-arginyl-L-leucyl-
 (9CI)
 SQL 5
 MF C37 H59 N9 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Prolinamide, 4-amino-N-(2-methylpropyl)-N-(trifluoroacetyl)-L-
 phenylalanyl-(2S)-2-cyclohexylglycyl-L-arginyl-L-leucyl- (9CI)
 SQL 5
 MF C40 H63 F3 N10 O6

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

```
L21 21 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN
IN   L-Cysteinamide, L-alanyl-L-asparaginyl-L-tryptophyl-L-arginyl-L-cysteinyl-
    L-cysteinyl-L-leucyl-L-isoleucyl-L-prolyl-L-alanyl-L-cysteinyl-L-arginyl-L-
    arginyl-L-asparaginyl-L-histidyl-L-lysyl-L-lysyl-L-phenylalanyl-, cyclic
    (5→11), (6→19)-bis(disulfide) (9CI)
SQL 19
MF   C99 H156 N36 O21 S4
```



*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- α -
 glutamyl-5-methyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-,
 cyclic (3 \rightarrow 9)-disulfide (9CI)
 SQL 9
 MF C61 H81 N19 O13 S2


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Cysteinamide, N-acetyl-L- α -aspartyl-L-leucyl-L-glutaminyl-L-cysteinyl-L-alanyl-L-isoleucyl-L-lysyl-L-cysteinyl-L-arginyl-L-alanylglycyl-L- α -glutamyl-L-prolyl-L-alanyl-L-glutaminyl-L-cysteinyl-L-asparaginyl-, cyclic (4 \rightarrow 16), (8 \rightarrow 18)-bis(disulfide) (9CI)
SQL 18
MF C77 H126 N26 O26 S4


RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***


L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Argininamide, 2,2'-[[5-(aminocarbonyl)-1,3-phenylene]bis(methylene)]bis[N-[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]-L- α -aspartyl- (9CI)
MF C55 H67 Cl4 N13 O15

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Prolinamide, 4-fluoro-N-(3-mercapto-1-oxopropyl)-L-phenylalanyl-L-leucyl-L-leucyl-L-arginyl-L-asparaginyl- (9CI)
SQL 6

MF C39 H62 F N11 O8 S

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Glutamamide, N-(ethylsulfonyl)-1-methyl-D-tryptophyl-N1-[[4-(aminoiminomethyl)phenyl]methyl]- (9CI)

MF C27 H35 N7 O5 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Pentanediamide, N1-[[4-(aminoiminomethyl)phenyl]methyl]-2-[[(2R)-1-oxo-2-[(propylsulfonyl)amino]butyl]amino]-, (2S)-


MF C20 H32 N6 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Hexopyranuronamide, 1-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1,4-dideoxy-4-
 [(glycylornithyl)amino]- (9CI)
 MF C17 H28 N8 O7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Prolinamide, N-(dichloroacetyl)-L-tyrosyl-L-isoleucyl-L-arginyl-L-leucyl-
 (9CI)
 SQL 5
 MF C34 H53 C12 N9 O7

RELATED SEQUENCES AVAILABLE WITH SEQLINK


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Prolinamide, L-tryptophyl-L-isoleucyl-L-arginyl-L-asparaginyl- (9CI)
 SQL 5
 MF C32 H49 N11 O6



Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Glutamamide, 3-cyclohexyl-N-[(phenylmethyl)sulfonyl]-D-alanyl-N1-[[4-(aminoiminomethyl)phenyl]methyl]-N5-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaocetadec-1-yl)-, monohydrochloride (9CI)
 MF C44 H69 N7 O10 S . Cl H





Absolute stereochemistry.



```
L21 21 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN
IN   L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- $\alpha$ -
      glutamyl-L-histidyl-4-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl-,
      cyclic (3 $\rightarrow$ 9)-disulfide (9CI)
SQL 9
MF   C60 H78 Cl N19 O13 S2
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- α -
glutamyl-3-(1H-1,2,4-triazol-3-yl)-L-alanyl-D-phenylalanyl-L-arginyl-L-
tryptophyl-, cyclic (3 \rightarrow 9)-disulfide (9CI)
SQL 9
MF C59 H78 N20 O13 S2


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Prolinamide, L-seryl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-alanyl-L-
leucyl-L-glutamyl-L-seryl- (9CI)
SQL 10
MF C47 H81 N15 O13


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




L21 21 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Prolinamide, L-isoleucyl-L-arginyl-L-valyl-
SQL 4
MF C22 H42 N8 O4

Absolute stereochemistry.



```
L21 21 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN
IN   L-Cysteinamide, L-phenylalanyl-L-cysteinyl-L-alanyl-L-arginyl-L-cysteinyl-
      L- $\alpha$ -aspartyl-L-prolyl-, cyclic (5 $\rightarrow$ 8)-disulfide (9CI)
SQL 8
MF   C36 H54 N12 O10 S3
```

Absolute stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

```
=> e  L-Glutamamide,
3-(1,1'-biphenyl)-4-yl-N-(((3-carboxyphenyl)methyl)sulfonyl)-D-alanyl-N1-((4-(aminoiminomethyl)phenyl)methyl)-/cn
MISMATCHED QUOTE IN EXPAND TERM
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.
```

```
=> e  L-Glutamamide,
3-1,1'-biphenyl-4-yl-N-(((3-carboxyphenyl)methyl)sulfonyl)-D-alanyl-N1-((4-(aminoiminomethyl)phenyl)methyl)-/cn
MISMATCHED QUOTE IN EXPAND TERM
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.
```

```
=> e  L-Glutamamide,
3-(1,1-biphenyl)-4-yl-N-(((3-carboxyphenyl)methyl)sulfonyl)-D-alanyl-N1-((4-(aminoiminomethyl)phenyl)methyl)-/cn
E1      1      L-GLUTAMAMIDE, 3-(1,1'-BIPHENYL)-4-YL-N-(METHYLSULFONYL)-D-ALANYL-N1-((4-(AMINOIMINOMETHYL)PHENYL)METHYL)-/CN
E2      1      L-GLUTAMAMIDE, 3-(1,1'-BIPHENYL)-4-YL-N-(PROPYLSULFONYL)-D-ALANYL-N1-((4-(AMINOIMINOMETHYL)PHENYL)METHYL)-/CN
E3      0 --> L-GLUTAMAMIDE, 3-(1,1-BIPHENYL)-4-YL-N-(((3-CARBOXYPHENYL)METHYL)SULFONYL)-D-ALANYL-N1-((4-(AMINOIMINOMETHYL)PHENYL)METHYL)-/CN
E4      1      L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-L-ALANYL-L-THREONYL-L-ALPHA-ASPARTYL-L-LEUCYL-L-VALYL-L-ALANYL-L-ISOLEUCYL-/CN
E5      1      L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-L-ALANYL-N1-(2-HYDROXY-4-METHOXY-1-(2-METHYLPROPYL)-4-OXOBUTYL)-, (S-(R*,R*))-/CN
E6      1      L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-N-(3-PYRIDINYLCARBONYL)-L-ALANYL-N1-(4-((5-AMINO-1-(AMINOCARBONYL)PENTYL)AMINO)-2-HYDROXY-1-(2-METHYLPROPYL)-4-OXOBUTYL)-, (1S-(1R*,2R*,4(R*)))-/CN
E7      1      L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-N-(3-PYRIDINYLCARBONYL)-L-ALANYL-N1-(4-((5-AMINO-1-(AMINOCARBONYL)PENTYL)AMINO)-2-HYDROXY-1-(2-METHYLPROPYL)-4-OXOBUTYL)-, MONOHYDROCHLORIDE, (1S-(1R*,2R*,4(R*)))-/CN
E8      1      L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-N-(3-PYRIDINYLCARBONYL)-L-ALANYL-N1-(4-((5-AMINO-1-(HYDROXYMETHYL)PENTYL)AMINO)-2-HYDR
```

OXY-1-(2-METHYLPROPYL)-4-OXOBUTYL)-, (1S-(1R*,2R*,4(R*)))-/C
N

E9 1 L-GLUTAMAMIDE, 3-(1-NAPHTHALENYL)-N-(3-PYRIDINYLCARBONYL)-L-
ALANYL-N1-(4-((5-AMINO-1-(HYDROXYMETHYL)PENTYL)AMINO)-2-HYDR
OXY-1-(2-METHYLPROPYL)-4-OXOBUTYL)-, DIHYDROCHLORIDE, (1S-(1
R*,2R*,4(R*)))-/CN

E10 1 L-GLUTAMAMIDE, 3-(2-NAPHTHALENYL)-N-(2-THIENYLCARBONYL)-L-AL
ANYL-/CN

E11 1 L-GLUTAMAMIDE, 3-(3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-
4-YL)-N-(ETHYLSULFONYL)-D-ALANYL-N1-((4-(AMINOIMINOMETHYL)PH
ENYL)METHYL)-/CN

E12 1 L-GLUTAMAMIDE, 3-(3',5'-BIS(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-
4-YL)-N-(ETHYLSULFONYL)-D-ALANYL-N1-((4-CYANOPHENYL)METHYL)-
/CN


=> e2

L22 1 "L-GLUTAMAMIDE, 3-(1,1'-BIPHENYL)-4-YL-N-(PROPYLSULFONYL)-D-ALAN
YL-N1-((4-(AMINOIMINOMETHYL)PHENYL)METHYL)-"/CN

=> d 122

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 446847-11-6 REGISTRY
ED Entered STN: 05 Sep 2002
CN L-Glutamamide, 3-[1,1'-biphenyl]-4-yl-N-(propylsulfonyl)-D-alanyl-N1-
[[4-(aminoiminomethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H38 N6 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.75	498.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'CAPLUS' ENTERED AT 13:04:11 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> 122

L23 1 L22

=> d 123

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:615652 CAPLUS
DN 137:169797
TI Preparation of peptide derivatives as factor VIIa inhibitors
IN Shiraishi, Takuya; Kadono, Shojiro; Haramura, Masayuki; Sato, Haruhiko; Kozono, Toshiro; Koga, Takaki; Sakamoto, Akihisa
PA Chugai Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2002062829	A1	20020815	WO 2002-JP883	20020204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002230136	A1	20020819	AU 2002-230136	20020204
	EP 1364960	A1	20031126	EP 2002-711294	20020204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20040087511	A1	20040506	US 2003-470801	20030801

US 7001887 B2 20060221
PRAI JP 2001-27474 A 20010202
WO 2002-JP883 W 20020204
OS MARPAT 137:169797
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.09	502.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'REGISTRY' ENTERED AT 13:08:03 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 08:03:28 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 08:04:09 ON 14 JUL 2008

FILE 'REGISTRY' ENTERED AT 08:14:42 ON 14 JUL 2008

L1 STRUCTURE UPLOADED
L2 0 SEARCH L1 SSS SAM
L3 0 SEARCH L1 EXACT FULL
L4 STRUCTURE UPLOADED
L5 0 SEARCH L4 SSS SAM
L6 0 SEARCH L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 4 SEARCH L7 SSS SAM
L9 STRUCTURE UPLOADED
L10 4 SEARCH L9 SSS SAM
L11 2858 SEARCH L9 SSS FULL
SAVE TEMP L11 RAWMSTRSET/A

FILE 'CAPLUS' ENTERED AT 09:20:25 ON 14 JUL 2008

L12 653 L11
L13 12764 UROKINASE
L14 26 L12 AND L13
L15 37753 ARG
L16 37753 L15 AND L15
L17 0 L14 AND L15
L18 123282 ARGININE
L19 4 L14 AND L18
SAVE TEMP L14 FNDREFS/A
SAVE TEMP ALL URKINSRCH/L

FILE 'REGISTRY' ENTERED AT 12:58:22 ON 14 JUL 2008

L20 STRUCTURE UPLOADED
L21 21 SEARCH L20 SSS SAM SUB=L11
E L-GLUTAMAMIDE, 3-(1,1-BIPHENYL)-4-YL-N-((3-CARBOXYPHENYL)M
L22 1 E2

FILE 'CAPLUS' ENTERED AT 13:04:11 ON 14 JUL 2008

L23 1 L22

FILE 'REGISTRY' ENTERED AT 13:08:03 ON 14 JUL 2008

=> search l20 subset=l11 sss full
FULL SUBSET SEARCH INITIATED 13:08:46 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1411 TO ITERATE




100.0% PROCESSED 1411 ITERATIONS 490 ANSWERS
SEARCH TIME: 00.00.01

L24 490 SEA SUB=L11 SSS FUL L20

=> d scan

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Prolinamide, L-cysteinyglycylglycylglycyl-L-arginyl-L-isoleucyl-L-tyrosyl-L-glutaminyl-L-isoleucyl-L-alanyl-L-lysyl-L-arginyl-L-arginyl-L-threonyl-L-arginyl-L-valyl-
SQL 17
MF C82 H144 N32 O20 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Prolinamide, L-threonyl-L-tryptophyl-L-alanyl-L-arginyl-L-asparaginyl-S-
[(acetylamino)methyl]-L-cysteinyl-L-tyrosyl-L-asparaginyl-L-valyl-L-
cysteinyl-L-arginyl-L-leucyl-


SQL 13

MF C72 H112 N24 O18 S2


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN L-Cysteinamide, N-acetyl-L- α -aspartyl-L-leucyl-L-glutaminyl-L-
cysteinyl-L-alanyl-L-isoleucyl-L-lysyl-L-cysteinyl-L-arginyl-L-


alanylglycyl-L- α -glutamyl-L-prolyl-L-alanyl-L-glutaminyl-L-cysteinyl-
L-asparaginyl-, cyclic (4 \rightarrow 16), (8 \rightarrow 18)-bis(disulfide) (9CI)
SQL 18
MF C77 H126 N26 O26 S4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Glutamamide, 3-[1,1'-biphenyl]-4-yl-N-(ethylsulfonyl)-L-alanyl-N1-[[4-(
aminoiminomethyl)phenyl]methyl]- (9CI)
MF C30 H36 N6 O5 S

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- α -
glutamyl-3-(4-pyridinyl)-L-alanyl-D-phenylalanyl-L-arginyl-L-tryptophyl-,
cyclic (3 \rightarrow 9)-disulfide (9CI)
SQL 9
MF C62 H80 N18 O13 S2

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- α -
 glutamyl-1-(phenylmethyl)-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-
 , cyclic (3 \rightarrow 9)-disulfide (9CI)
 SQL 9
 MF C67 H85 N19 O13 S2

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- α -
 glutamyl-1-methyl-D-histidyl-4-fluoro-D-phenylalanyl-L-arginyl-L-
 tryptophyl-, cyclic (3 \rightarrow 9)-disulfide (9CI)
 SQL 9
 MF C61 H80 F N19 O13 S2

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L-valyl-L-
 histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic
 (3→9)-disulfide (9CI)
 SQL 9
 MF C60 H81 N19 O11 S2

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
L24 490 ANSWERS   REGISTRY   COPYRIGHT 2008 ACS on STN
IN   L-Cysteinamide, N-acetyl-L-tyrosyl-L-arginyl-L-cysteinyl-L- $\alpha$ -
      aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic
      (3 $\rightarrow$ 9)-disulfide (9CI)
SQL 9
MF   C59 H77 N19 O13 S2
```

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, L-phenylalanyl-L-asparaginyl-L-tryptophyl-L-arginyl-L-
 cysteinyl-L-cysteinyl-L-leucyl-L-isoleucyl-L-prolyl-L-alanyl-L-cysteinyl-L-
 arginyl-L-arginyl-L-asparaginyl-L-histidyl-L-lysyl-L-lysyl-L-lysyl-,
 cyclic (5→11), (6→19)-bis(disulfide) (9CI)
 SQL 19
 MF C102 H163 N37 O21 S4

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

L24 490 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Cysteinamide, L-phenylalanyl-L-asparaginyl-L-tryptophyl-L-arginyl-L-
 cysteinyl-L-cysteinyl-L-alanyl-L-isoleucyl-L-prolyl-L-alanyl-L-cysteinyl-L-
 arginyl-L-arginyl-L-asparaginyl-L-histidyl-L-lysyl-L-lysyl-L-phenylalanyl-,
 cyclic (5→11), (6→19)-bis(disulfide) (9CI)
 SQL 19
 MF C102 H154 N36 O21 S4

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
43.02	545.45

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'CAPLUS' ENTERED AT 13:09:12 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> l24

L25 104 L24

=> d his

(FILE 'HOME' ENTERED AT 08:03:28 ON 14 JUL 2008)

FILE 'REGISTRY' ENTERED AT 08:04:09 ON 14 JUL 2008

FILE 'REGISTRY' ENTERED AT 08:14:42 ON 14 JUL 2008

L1 STRUCTURE UPLOADED
L2 0 SEARCH L1 SSS SAM
L3 0 SEARCH L1 EXACT FULL
L4 STRUCTURE UPLOADED
L5 0 SEARCH L4 SSS SAM
L6 0 SEARCH L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 4 SEARCH L7 SSS SAM
L9 STRUCTURE UPLOADED
L10 4 SEARCH L9 SSS SAM
L11 2858 SEARCH L9 SSS FULL
SAVE TEMP L11 RAWMSTRSET/A

FILE 'CAPLUS' ENTERED AT 09:20:25 ON 14 JUL 2008

L12 653 L11
L13 12764 UROKINASE
L14 26 L12 AND L13
L15 37753 ARG
L16 37753 L15 AND L15
L17 0 L14 AND L15
L18 123282 ARGININE
L19 4 L14 AND L18
SAVE TEMP L14 FNDREFS/A
SAVE TEMP ALL URKINSRCH/L

FILE 'REGISTRY' ENTERED AT 12:58:22 ON 14 JUL 2008
L20 STRUCTURE UPLOADED
L21 21 SEARCH L20 SSS SAM SUB=L11
E L-GLUTAMAMIDE, 3-(1,1-BIPHENYL)-4-YL-N-((3-CARBOXYPHENYL)M
L22 1 E2

FILE 'CAPLUS' ENTERED AT 13:04:11 ON 14 JUL 2008
L23 1 L22

FILE 'REGISTRY' ENTERED AT 13:08:03 ON 14 JUL 2008
L24 490 SEARCH L20 SSS FULL SUB=L11

FILE 'CAPLUS' ENTERED AT 13:09:12 ON 14 JUL 2008
L25 104 L24

=> l13 and l25

L26 5 L13 AND L25

=> d l26 1-5 ti

L26 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Fibrin targeted therapeutics, particularly peptidomimetics, their
preparation and use in the treatment of thromboembolism, infection, and
cancer

L26 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI New substrate analogue inhibitors of factor Xa containing
4-amidinobenzylamide as P1 residue: part 1

L26 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Design of Novel and Selective Inhibitors of Urokinase-type
Plasminogen Activator with Improved Pharmacokinetic Properties for Use as
Antimetastatic Agents

L26 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Use of acylated 4-amidino- and 4-guanidinobenzylamines for inhibition of
plasma kallikrein

L26 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of guanidinybenzene-derivative dipeptide conjugate
urokinase inhibitors as pharmaceuticals for use in the treatment
or diagnosis of metastatic tumors

=> d l26 3-5 ti fbib abs

L26 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Design of Novel and Selective Inhibitors of Urokinase-type
Plasminogen Activator with Improved Pharmacokinetic Properties for Use as
Antimetastatic Agents
AN 2004:617178 CAPLUS
DN 141:270994
TI Design of Novel and Selective Inhibitors of Urokinase-type
Plasminogen Activator with Improved Pharmacokinetic Properties for Use as
Antimetastatic Agents
AU Schweinitz, Andrea; Steinmetzer, Torsten; Banke, Ingo J.; Arlt, Matthias
J. E.; Stuerzebecher, Anne; Schuster, Oliver; Geissler, Andreas;
Giersiefen, Helmut; Zeslawska, Ewa; Jacob, Uwe; Krueger, Achim;
Stuerzebecher, Joerg
CS Curacyte Chemistry GmbH, Jena, D-07745, Germany
SO Journal of Biological Chemistry (2004), 279(32), 33613-33622

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

OS CASREACT 141:270994

AB The serine protease urokinase-type plasminogen activator (uPA) interacts with a specific receptor (uPAR) on the surface of various cell types, including tumor cells, and plays a crucial role in pericellular proteolysis. High levels of uPA and uPAR often correlate with poor prognosis of cancer patients. Therefore, the specific inhibition of uPA with small mol. active-site inhibitors is one strategy to decrease the invasive and metastatic activity of tumor cells. The authors have developed a series of highly potent and selective uPA inhibitors with a C-terminal 4-amidinobenzylamide residue. Optimization was directed toward reducing the fast elimination from circulation that was observed with initial analogs. The x-ray structures of three inhibitor/uPA complexes have been solved and were used to improve the inhibition efficacy. One of the most potent and selective derivs., benzylsulfonyl-D-Ser-Ser-4-amidinobenzylamide (inhibitor 26), inhibits uPA with a K_i of 20 nM. This inhibitor was used in a fibrosarcoma model in nude mice using lacZ-tagged human HT1080 cells, to prevent exptl. lung metastasis formation. Compared with control (100%), an inhibitor dose of 2 + 1.5 mg/kg/day reduced the number of exptl. metastases to 4.6±1%. Under these conditions inhibitor 26 also significantly prolonged survival. All mice from the control group died within 43 days after tumor cell inoculation, whereas 50% of mice from the inhibitor-treated group survived more than 117 days. This study demonstrates that the specific inhibition of uPA by these inhibitors may be a useful strategy for the treatment of cancer to prevent metastasis.

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of acylated 4-amidino- and 4-guanidinobenzylamines for inhibition of plasma kallikrein

AN 2004:605410 CAPLUS

DN 141:150999

TI Use of acylated 4-amidino- and 4-guanidinobenzylamines for inhibition of plasma kallikrein

IN Sturzebecher, Jorg; Steinmetzer, Torsten; Schweinitz, Andrea

PA Curacyte Chemistry GmbH, Germany

SO Ger. Offen., 40 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 10301300	A1	20040729	DE 2003-10301300	20030115
	AU 2004204358	A1	20040729	AU 2004-204358	20040115
				DE 2003-10301300	A 20030115
				WO 2004-EP247	W 20040115
	CA 2513280	A1	20040729	CA 2004-2513280	20040115
				DE 2003-10301300	A 20030115
				WO 2004-EP247	W 20040115
	WO 2004062657	A1	20040729	WO 2004-EP247	20040115
	WO 2004062657	A8	20050106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
				DE 2003-10301300	A 20030115

EP 1583526	A1	20051012	EP 2004-702332	20040115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			DE 2003-10301300	A 20030115
			WO 2004-EP247	W 20040115
JP 2006516277	T	20060629	JP 2006-500572	20040115
			DE 2003-10301300	A 20030115
			WO 2004-EP247	W 20040115
US 20060148901	A1	20060706	US 2006-540958	20060103
			DE 2003-10301300	A 20030115
			WO 2004-EP247	W 20040115

AB The invention discloses the use of acylated 4-amidino or 4-guanidinobenzylamines P4-P3-P2-P1 [P4 = single or multiple (un)substituted benzylsulfonyl; P3 = single or multiple (un)substituted, (un)natural α -amino or α -imino acid in D-configuration; P2 = single or multiple (un)substituted, (un)natural α -amino or α -imino acid in L-configuration; P1 = single or multiple (un)substituted 4-amidino or 4-guanidinobenzylamine] for inhibition of plasma kallikrein (PK). The PK inhibitors of the invention are used for prevention of coagulation activation on artificial surfaces and for systemic addition as anticoagulants/antithrombotics, particularly for prevention of the coagulation activation on artificial surfaces, in order to prevent thromboembolic events. Compound preparation is included.

L26 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of guanidinylnbenzene-derivative dipeptide conjugate urokinase inhibitors as pharmaceuticals for use in the treatment or diagnosis of metastatic tumors

AN 2003:737714 CAPLUS

DN 139:246220

TI Synthesis of guanidinylnbenzene-derivative dipeptide conjugate urokinase inhibitors as pharmaceuticals for use in the treatment or diagnosis of metastatic tumors

IN Sturzebecher, Jorg; Steinmetzer, Torsten; Schweinitz, Andrea

PA Curacyte Ag, Germany

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003076391	A2	20030918	WO 2003-EP2489	20030311	
	WO 2003076391	A3	20040122			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
				DE 2002-10210592	A 20020311	
				DE 2002-10245059	A 20020926	
				DE 2002-10261435	A 20021228	
	DE 10210592	A1	20031002	DE 2002-10210592	20020311	
	CA 2478409	A1	20030918	CA 2003-2478409	20030311	
				DE 2002-10210592	A 20020311	
				DE 2002-10245059	A 20020926	
				DE 2002-10261435	A 20021228	

AU 2003219039	A1	20030922	WO 2003-EP2489	W	20030311
			AU 2003-219039		20030311
			DE 2002-10210592	A	20020311
			DE 2002-10245059	A	20020926
			DE 2002-10261435	A	20021228
			WO 2003-EP2489	W	20030311
EP 1485345	A2	20041215	EP 2003-714803		20030311
EP 1485345	B1	20080625			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
			DE 2002-10210592	A	20020311
			DE 2002-10245059	A	20020926
			DE 2002-10261435	A	20021228
			WO 2003-EP2489	W	20030311
JP 2005526762	T	20050908	JP 2003-574613		20030311
			DE 2002-10210592	A	20020311
			DE 2002-10245059	A	20020926
			DE 2002-10261435	A	20021228
			WO 2003-EP2489	W	20030311
US 20050176993	A1	20050811	US 2005-506579		20050413
			DE 2002-10210592	A	20020311
			DE 2002-10245059	A	20020926
			DE 2002-10261435	A	20021228
			WO 2003-EP2489	W	20030311

OS MARPAT 139:246220

AB Title compds., [e.g., PhCH₂SO₂-D-Ser-Ser-NHCH₂-4-C₆H₄-C(:NH)NH₂ (I)], were prepared and tested as urokinase inhibitors, for use in the prophylaxis and diagnosis of a tumor and for reducing the formation of tumor metastases. Thus, (H₃C)₃COC(O)-Ser(CH₂PH)-OH was reacted with H₂NCH₂-4-C₆H₄-C(:NH)NH₂.HCl, the amine protecting group removed, and the intermediate reacted with PhCH₂SO₂-D-Ser(C(CH₃)₃)-OH; the intermediate protected dipeptide was purified by isolation as first the acetate salt, then the trifluoroacetate salt, in a final yield of 24.64%. In in vivo tests against fibrosarcoma using white mice, after 22 days I reduced metastatic lung tumors by 4.6%, compared with a control group.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.97	557.42

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.40	-5.60

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:11:02 ON 14 JUL 2008